Headquarters: Mechelen, Belgium
Ticker: GLPG (NASDAQ, Euronext)
Founded: 1999
Website: glpg.com
Galapagos NV is a Belgian biotechnology company headquartered in Mechelen, Belgium, founded in 1999. The company focuses on discovering and developing novel small molecule therapies for oncology, immunology, and inflammatory diseases. While not primarily focused on neurodegenerative diseases, Galapagos has explored programs in CNS disorders and maintains a significant presence in inflammation research relevant to neuroinflammation.
Galapagos has emerged as one of Europe's leading biotechnology companies, with a proprietary target discovery platform and a track record of bringing drugs through clinical development.
| Area |
Lead Program |
Mechanism |
Phase |
| Oncology |
GLPG5101 |
CAR-T |
Phase 1/2 |
| Immunology |
Jyseleca (filgotinib) |
JAK1 Inhibitor |
Approved (EU, Japan) |
| Inflammation |
GLPG3668 |
PDE4 Inhibitor |
Phase 1 |
| Oncology |
GLPG-1 |
Undisclosed |
Discovery |
Filgotinib is a selective JAK1 inhibitor developed by Galapagos and commercialized in partnership with Gilead Sciences:
- Approved Indications: Rheumatoid arthritis (RA), ulcerative colitis
- Mechanism: Selective inhibition of JAK1, reducing inflammatory cytokine signaling
- Global Rights: Gilead holds commercialization rights outside Europe
¶ Neurology and Neuroinflammation
While Galapagos has deprioritized dedicated CNS programs, their JAK1 inhibitor has potential applications in neuroinflammation:
- Alzheimer's Disease Research: JAK/STAT pathway involvement in neuroinflammation
- Parkinson's Disease: Potential for reducing microglial activation
- Multiple Sclerosis: Investigated in preclinical models
Galapagos has built a proprietary target discovery platform:
- RNAi Screening: Genome-wide loss-of-function screens
- Bioinformatics: Integration of human genetics and omics data
- Patient-Derived Models: Primary cells and organoids for validation
The company maintains expertise in:
- Medicinal Chemistry: Structure-based drug design
- ADMET: Integrated ADMET profiling
- Formulation: Oral and topical delivery
Following acquisition of Cellistic, Galapagos has expanded into cell therapy:
- Allogeneic CAR-T: Off-the-shelf CAR-T candidates
- iPSC Platform: Induced pluripotent stem cell-derived therapies
- Manufacturing: European manufacturing capabilities
Galapagos has advanced multiple programs through clinical development:
- Phase 3: Completed pivotal trials in rheumatoid arthritis
- Phase 2: Ongoing studies in inflammatory bowel disease
- Phase 1: First-in-human studies for new candidates
- 2019: EMA approval of filgotinib for rheumatoid arthritis
- 2020: Japanese approval of filgotinib
- 2021: FDA complete response letter (requiring additional studies)
One of the largest biotech partnerships in European history:
- Total Deal Value: $5.4 billion (including $3.95 billion upfront)
- Scope: Global development and commercialization of filgotinib and other programs
- Programs Included: 10+ clinical programs across multiple therapeutic areas
- Reversion Rights: Galapagos regained US rights in 2022
- Lundbeck: CNS research collaboration (historical)
- Pfizer: Target discovery collaboration (historical)
- Academic Partnerships: Various European university collaborations
| Metric |
Value |
| Market Cap |
~$3 billion (2024) |
| Cash Position |
Strong following Gilead reversion |
| Revenue |
~€500M (2023) |
| Employees |
~2,500 |
- 1999: Founded in Belgium by Dr. Onno van de Stolpe
- 2005: First partnership with Pfizer
- 2015: IPO on NASDAQ raised €380 million
- 2019: Historic Gilead partnership announced
- 2021: Strategic restructuring and CEO transition
- 2022: Regained US rights to filgotinib from Gilead
- CEO: Paul Stoffels (former Johnson & Johnson executive)
- CSO: Dr. Piet Wigerinck
- CFO: Bart Filius
¶ Challenges and Considerations
-
US Regulatory: FDA has not yet approved filgotinib
-
Competition: JAK inhibitor class faces safety concerns
-
CNS Strategy: Company has shifted away from CNS programs
-
Gilead Relationship: Post-partnership strategy evolution
-
Alzheimer's Disease
-
Parkinson's Disease
-
JAK Inhibitors
-
Gene Therapy